Furthermore, we provide evidence that pharmacological inhibition of CRM1 activity alleviates the progeroid cellular phenotype (Graphical abstract), which delineates CRM1 as potential therapeutic target for HGPS and other aging‐related diseases. This evidence concerns the gene XPO1 and Hutchinson-Gilford progeria syndrome.